These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 15548128)
1. Market withdrawal of Vioxx: is it time to rethink the use of COX-2 inhibitors? Ortiz E J Manag Care Pharm; 2004; 10(6):551-4. PubMed ID: 15548128 [TBL] [Abstract][Full Text] [Related]
2. COX-2 inhibitors--lessons in drug safety. Psaty BM; Furberg CD N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946 [No Abstract] [Full Text] [Related]
3. Vioxx risk could signify trouble in class. Frantz S Nat Rev Drug Discov; 2004 Nov; 3(11):899-901. PubMed ID: 15558856 [No Abstract] [Full Text] [Related]
4. Coxibs and cardiovascular disease. Fitzgerald GA N Engl J Med; 2004 Oct; 351(17):1709-11. PubMed ID: 15470192 [No Abstract] [Full Text] [Related]
5. COX-2 inhibitors--a lesson in unexpected problems. Drazen JM N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947 [No Abstract] [Full Text] [Related]
6. [Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?]. Scheen AJ Rev Med Liege; 2004 Oct; 59(10):565-9. PubMed ID: 15623076 [TBL] [Abstract][Full Text] [Related]
7. Differences between COX-2-specific inhibitors: clinical and economic implications. Sonnenblick EH Am J Manag Care; 2002 Oct; 8(15 Suppl):S428-30. PubMed ID: 12416792 [No Abstract] [Full Text] [Related]
8. FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. Lenzer J BMJ; 2005 Feb; 330(7489):440. PubMed ID: 15731142 [No Abstract] [Full Text] [Related]
9. COX-2 inhibitors: cancer prevention or cardiovascular risk? Senior K Lancet Oncol; 2005 Feb; 6(2):68. PubMed ID: 15704289 [No Abstract] [Full Text] [Related]
10. MI risk prompts rofecoxib withdrawal. Thompson CA Am J Health Syst Pharm; 2004 Nov; 61(21):2234-6, 2238. PubMed ID: 15552625 [No Abstract] [Full Text] [Related]
12. The Vioxx debacle revisited. Manthous CA Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904 [No Abstract] [Full Text] [Related]
13. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease. Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850 [No Abstract] [Full Text] [Related]
14. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs. Atkinson HG Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146 [No Abstract] [Full Text] [Related]
15. The lessons of Vioxx. Frazier KC N Engl J Med; 2005 Sep; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497 [No Abstract] [Full Text] [Related]
16. Vioxx, the implosion of Merck, and aftershocks at the FDA. Horton R Lancet; 2004 Dec 4-10; 364(9450):1995-6. PubMed ID: 15582041 [No Abstract] [Full Text] [Related]
17. Cardiovascular complications of COX2 selective inhibitors cause considerable concern. Hedner T; Himmelmann A Blood Press; 2004; 13(5):260-1. PubMed ID: 15545147 [No Abstract] [Full Text] [Related]